Similarly, the incidence of grade 1 or 2 interstitial lung disease was higher in an Asian subset of patients in BOLERO-2, although the trial population was different (HR+, HER2– advanced breast cancer progressing on prior nonsteroidal aromatase inhibitors treated with everolimus plus exemestane) [19]. Here, ERBB2 is linked to breast cancer.